Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Heidelberg
Age
50–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed invasive breast cancer
Total tumor size \< 2.5 cm
cN0
estrogen receptor positive, HER2-receptor negative on immunohistochemistry
age \>= 50 years
ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2
Ability of subject to understand character and individual consequences of the clinical trial
Written informed consent (must be available before enrolment in the trial)
You may not be if
G3
Extensive microcalcifications
Invasive lobular carcinoma
Clinically involved lymph nodes
No invasive axillary lymph node staging planned
Patients with significant mental or physical comorbidities that preclude regular follow-up
Neoadjuvant chemotherapy or neoadjuvant endocrine therapy
previous radiotherapy of the breast
Known carcinoma \< 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy
Pregnant or lactating women
Participation in another competing clinical study or observation period of competing trials
Clareo Health | Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer
